Curium, in collaboration with nuclear cardiology leaders, announces immediate return of Thallous Chloride TI 201 Injection in the U.S. to support high-stakes cardiac imaging needs

Reintroduction reflects clinician input and Curium investments to support reliable, long-term U.S. supply BOSTON, July 27, 2026 (GLOBE NEWSWIRE) — Curium™ announced today the immediate reintroduction of Thallous Chloride TI 201 Injection (commonly known as thallium 201) in the U.S., restoring access to a radiopharmaceutical used in nuclear cardiology after production ceased in 2022. Renewed […]